Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas P Corner

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
RSC Chemical Biology|March 6, 2025
Biochemical investigations using mass spectrometry to monitor JMJD6-catalysed hydroxylation of multi-lysine containing bromodomain-derived substratesThomas P Corner, Eidarus Salah, Anthony Tumber, et al.
RSC Chemical Biology|June 9, 2023
Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5Anthony Tumber, Eidarus Salah, Lennart Brewitz, et al.
Chemmedchem|October 31, 2025
Profiling Inhibitor Scaffolds for the Cancer Target Jumonji-C Domain-Containing Protein 6Thomas P Corner, Eidarus Salah, Anthony Tumber, et al.
Journal of Medicinal Chemistry|April 23, 2025
Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine HydroxylaseThomas P Corner, Anthony Tumber, Eidarus Salah, et al.
Chemmedchem|September 18, 2024
Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and EnarodustatThomas P Corner, Eidarus Salah, Anthony Tumber, et al.
Bioorganic & Medicinal Chemistry|January 23, 2024
Selective targeting of human TET1 by cyclic peptide inhibitors: Insights from biochemical profilingKlemensas Šimelis, Hilal Saraç, Eidarus Salah, et al.
Journal of Medicinal Chemistry|October 21, 2024
Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver DiseaseYue Wu, Zewei Zhang, Haiping Cai, et al.
Chemical Science|November 16, 2023
Structure-guided optimisation of <i>N</i>-hydroxythiazole-derived inhibitors of factor inhibiting hypoxia-inducible factor-αThomas P Corner, Ryan Z R Teo, Yue Wu, et al.
Journal of Medicinal Chemistry|August 1, 2023
5-Substituted Pyridine-2,4-dicarboxylate Derivatives Have Potential for Selective Inhibition of Human Jumonji-C Domain-Containing Protein 5Lennart Brewitz, Yu Nakashima, Sonia K Piasecka, et al.
Angewandte Chemie (International Ed. in English)|June 26, 2024
A Small-Molecule Inhibitor of Factor Inhibiting HIF Binding to a Tyrosine-Flip Pocket for the Treatment of ObesityYue Wu, Yafen Chen, Thomas P Corner, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
RSC Chemical Biology|March 6, 2025
Biochemical investigations using mass spectrometry to monitor JMJD6-catalysed hydroxylation of multi-lysine containing bromodomain-derived substratesThomas P Corner, Eidarus Salah, Anthony Tumber, et al.
RSC Chemical Biology|June 9, 2023
Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5Anthony Tumber, Eidarus Salah, Lennart Brewitz, et al.
Chemmedchem|October 31, 2025
Profiling Inhibitor Scaffolds for the Cancer Target Jumonji-C Domain-Containing Protein 6Thomas P Corner, Eidarus Salah, Anthony Tumber, et al.
Journal of Medicinal Chemistry|April 23, 2025
Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine HydroxylaseThomas P Corner, Anthony Tumber, Eidarus Salah, et al.
Chemmedchem|September 18, 2024
Crystallographic and Selectivity Studies on the Approved HIF Prolyl Hydroxylase Inhibitors Desidustat and EnarodustatThomas P Corner, Eidarus Salah, Anthony Tumber, et al.
Bioorganic & Medicinal Chemistry|January 23, 2024
Selective targeting of human TET1 by cyclic peptide inhibitors: Insights from biochemical profilingKlemensas Šimelis, Hilal Saraç, Eidarus Salah, et al.
Journal of Medicinal Chemistry|October 21, 2024
Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver DiseaseYue Wu, Zewei Zhang, Haiping Cai, et al.
Chemical Science|November 16, 2023
Structure-guided optimisation of <i>N</i>-hydroxythiazole-derived inhibitors of factor inhibiting hypoxia-inducible factor-αThomas P Corner, Ryan Z R Teo, Yue Wu, et al.
Journal of Medicinal Chemistry|August 1, 2023
5-Substituted Pyridine-2,4-dicarboxylate Derivatives Have Potential for Selective Inhibition of Human Jumonji-C Domain-Containing Protein 5Lennart Brewitz, Yu Nakashima, Sonia K Piasecka, et al.
Angewandte Chemie (International Ed. in English)|June 26, 2024
A Small-Molecule Inhibitor of Factor Inhibiting HIF Binding to a Tyrosine-Flip Pocket for the Treatment of ObesityYue Wu, Yafen Chen, Thomas P Corner, et al.
Pageof 1